31021425|t|Acteoside inhibits autophagic apoptosis of retinal ganglion cells to rescue glaucoma-induced optic atrophy.
31021425|a|BACKGROUND: Glaucoma is the world's second biggest cause of blindness, and patients progressively lose their eyesight. The current clinical treatment for glaucoma involves controlling intraocular pressure with drugs or surgery; however, some patients still progressively lose their eyesight. This treatment is also similar to the treatment of traumatic optic neuropathy. Thus, saving retinal ganglion cells (RGCs) from apoptosis is essential. METHODS: The role of Acteoside on autophagy modulation in the 661 W cell line. RESULTS: In this study, we first find that Acteoside inhibits autophagy, Rapamycin alleviates this inhibition and the PI3K inhibitor, 3-MA or LY294002, synergistically promotes it. In a mechanistic study, we find that Optineurin (OPTN) mediates Acteoside regulation of autophagy. OPTN overexpression or knockdown activates or inhibits autophagy, respectively. OPTN is inhibited by autophagy inhibitors, such as Acteoside and 3-MA and is promoted by the autophagy activator, Rapamycin. Meanwhile, PI3K and AKT are elevated by Acteoside and 3-MA and inhibited by Rapamycin. Finally, we find that Acteoside inhibits apoptosis in parallel to autophagy and that this inhibition is also mediated by OPTN. CONCLUSION: In summary, we conclude that Acteoside inhibits autophagy-induced apoptosis in RGCs through the OPTN and PI3K/AKT/mTOR pathway, and glaucoma patients may benefit from Acteoside treatment alone or in combination with other autophagy inhibitors.
31021425	0	9	Acteoside	Chemical	MESH:C058956
31021425	76	84	glaucoma	Disease	MESH:D005901
31021425	93	106	optic atrophy	Disease	MESH:D009896
31021425	120	128	Glaucoma	Disease	MESH:D005901
31021425	168	177	blindness	Disease	MESH:D001766
31021425	183	191	patients	Species	9606
31021425	262	270	glaucoma	Disease	MESH:D005901
31021425	350	358	patients	Species	9606
31021425	451	477	traumatic optic neuropathy	Disease	MESH:D020221
31021425	572	581	Acteoside	Chemical	MESH:C058956
31021425	613	618	661 W	CellLine	CVCL:6240
31021425	673	682	Acteoside	Chemical	MESH:C058956
31021425	703	712	Rapamycin	Chemical	MESH:D020123
31021425	764	768	3-MA	Chemical	-
31021425	772	780	LY294002	Chemical	MESH:C085911
31021425	848	858	Optineurin	Gene	71648
31021425	860	864	OPTN	Gene	71648
31021425	875	884	Acteoside	Chemical	MESH:C058956
31021425	910	914	OPTN	Gene	71648
31021425	990	994	OPTN	Gene	71648
31021425	1041	1050	Acteoside	Chemical	MESH:C058956
31021425	1055	1059	3-MA	Chemical	-
31021425	1104	1113	Rapamycin	Chemical	MESH:D020123
31021425	1135	1138	AKT	Gene	11651
31021425	1155	1164	Acteoside	Chemical	MESH:C058956
31021425	1169	1173	3-MA	Chemical	-
31021425	1191	1200	Rapamycin	Chemical	MESH:D020123
31021425	1224	1233	Acteoside	Chemical	MESH:C058956
31021425	1323	1327	OPTN	Gene	71648
31021425	1370	1379	Acteoside	Chemical	MESH:C058956
31021425	1437	1441	OPTN	Gene	71648
31021425	1451	1454	AKT	Gene	11651
31021425	1455	1459	mTOR	Gene	56717
31021425	1473	1481	glaucoma	Disease	MESH:D005901
31021425	1482	1490	patients	Species	9606
31021425	1508	1517	Acteoside	Chemical	MESH:C058956
31021425	Positive_Correlation	MESH:C058956	11651
31021425	Negative_Correlation	MESH:C058956	MESH:D009896
31021425	Positive_Correlation	MESH:D020123	71648
31021425	Negative_Correlation	MESH:C058956	MESH:D005901
31021425	Negative_Correlation	MESH:D020123	11651
31021425	Association	MESH:C058956	71648
31021425	Association	MESH:C058956	56717

